Publicacións en colaboración con investigadores/as de Yale University (10)

2023

  1. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary

    Cancer discovery, Vol. 13, Núm. 3, pp. 552-569

2021

  1. A burned-out cd8+ t-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy

    Cancer Discovery, Vol. 11, Núm. 7, pp. 1700-1715

2020

  1. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

    Nature Medicine, Vol. 26, Núm. 5, pp. 688-692

2019

  1. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis

    Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673

  2. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

    Cell, Vol. 176, Núm. 1-2, pp. 334-347.e12

  3. Immunotherapy in non-small cell lung cancer: Facts and hopes

    Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4592-4602

  4. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus

    Science Translational Medicine, Vol. 11, Núm. 522

2018

  1. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

    Nature Communications, Vol. 9, Núm. 1

2017

  1. Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours

    Journal of Translational Medicine, Vol. 15, Núm. 1

2014

  1. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation

    Cancer Journal (United States), Vol. 20, Núm. 4, pp. 256-261